# US 2009/0253156 A1 · Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0253156 A1
- Document ID: US20090253156A1
- Status: Published application
- Kind: A1
- Application number: 11/744,705
- Filed: 2007-05-04
- Published: 2009-10-08
- Earliest claimed: 2006-05-05
- Assignees: PerkinElmer LAS, Inc.
- Inventors: Wayne F. Patton; Bing Xie
- Web page: https://patentgrep.com/patent/US20090253156A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The inventions relates to methods and kits for capture and/or analysis of kinases and/or phosphatases in one or more samples. In some embodiments, a kinase inhibitor, e.g. staurosporine or its derivative, is used to capture kinases from a sample. In some embodiments, a phosphatase inhibitor, e.g. microcystin or its derivative, is used to capture phosphatases from a sample. Methods for quantitative analysis of captured kinases and/or proteases are also provided. In some embodiments, quantitative analysis is accomplished using mass spectrometry. In addition, the invention provides kits related to same.

## Claims

### Claim 1

A method for analysis of proteins in a sample comprising:
a) contacting the sample with a first protein capture agent;
b) separating the proteins bound to the first protein capture agent from the sample;
c) digesting the proteins bound to the first protein capture agent with a protease to provide protein fragments having a scissile bond; and
d) analyzing the products of the protease digestion by mass spectrometry.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first protein capture agent is a kinase capture agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the kinase capture agent is a non-selective kinase capture agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the kinase capture agent is a kinase inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the kinase inhibitor is staurosporine or a staurosporine analog.

### Claim 6 (depends on 5)

The method of claim 5, wherein the staurosporine analog is selected from the group consisting of 7-hydroxystaurosporine, N-benzoylstaurosporine, 3-hydroxy-4′-N-methylstaurosporine, 3-hydroxy-4′-N-demethylstaurosporine, 3′-demethoxy-3′-hydroxy-4′-N-demethylstaurosporine, staurosporine aglycone and 4′-N-benzoyl staurosporine.

### Claim 7 (depends on 4)

The method of claim 4, wherein the kinase inhibitor is selected from the group consisting of KT 5720, K252, H-9, rottlerin, quercetin, hymenialdisine, SB 203580, myricetin, SU11248, roscovitine, EKB569 and SB202190.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first protein capture agent is labeled with a first member of an affinity pair.

### Claim 9 (depends on 8)

The method of claim 8, wherein the first member of an affinity pair is biotin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the first protein capture agent is a phosphatase capture agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the phosphatase capture agent is a phosphatase inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, tautomycin, microcystin, a microcystin derivative, calyculin A, calyculin B, calyculin C, calyculin D, calyculin E, calyculin F, calyculin G, calyculin H, cantharidin, thyrsferyl 23-acetate, isopalinurin, dragacidin, a dragacidin derivative, fostriecin, 1-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid and bis-(maltoato)-oxovanadium(IV).

### Claim 13 (depends on 10)

The method of claim 10, wherein the phosphatase capture agent is labeled with a first member of an affinity pair.

### Claim 14 (depends on 13)

The method of claim 13, wherein the first member of an affinity pair is biotin.

### Claim 15 (depends on 1)

The method of claim 1, wherein the protease is trypsin.

### Claim 16 (depends on 1)

The method of claim 1, wherein mass spectroscopy is tandem mass spectroscopy.

### Claim 17 (depends on 1)

The method of claim 1, further comprising
a) contacting the sample with a second protein capture agent;
b) separating the proteins bound to the second protein capture agent from the sample; and
c) digesting the proteins bound to the second protein capture agent with a protease to provide protein fragments comprising a scissile bond.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first protein capture gent is a kinase capture agent and the second protein capture agent is a kinase capture agent different from the first kinase capture agent.

### Claim 19 (depends on 17)

The method of claim 17, wherein the first protein capture agent is a kinase capture agent and the second protein capture agent is a phosphatase capture agent.

### Claim 20 (depends on 1)

The method of claim 1, further comprising:
a) providing to protein fragments having a scissile bond a calibrator peptide having a scissile bond and having the same amino acid composition and same mass as a protein fragment after protease digestion, wherein the calibrator peptide has a scissile bond in a different location from the protein fragment; and
b) analyzing the calibrator peptide by mass spectroscopy.

### Claim 21 (depends on 20)

The method of claim 20, wherein mass spectroscopy is tandem mass spectroscopy.

### Claim 22

A method for analysis of proteins from a plurality of samples comprising:
a) contacting each sample with a protein capture agent;
b) separating the proteins bound to the protein capture agent from each sample;
c) coupling a set of isobaric mass tags to the captured proteins or protein fragments, wherein proteins in each sample are coupled with a different isobaric mass tag from the set and wherein each isobaric mass tag in the set has a scissile bond in a different position than any other mass tag in the set;
d) digesting the captured proteins with a protease to provide protein fragments; and
e) detecting a plurality of isobaric mass tags by mass spectrometry in the same experiment.

### Claim 23 (depends on 22)

The method of claim 22, wherein the isobaric mass tags are coupled to the captured proteins prior to digestion with a protease.

### Claim 24 (depends on 22)

The method of claim 22, wherein the isobaric mass tags are coupled to the protein fragments resultant from the digestion of captured proteins with a protease.

### Claim 25 (depends on 22)

The method of claim 22, wherein each isobaric mass tag comprises a peptide.

### Claim 26 (depends on 22)

The method of claim 22, wherein the scissile bond is Asp-Pro bond.

### Claim 27

The method of clam 22, wherein mass spectrometry is tandem mass spectrometry.

### Claim 28 (depends on 22)

The method of claim 22, wherein the first protein capture agent is a kinase capture agent.

### Claim 29 (depends on 28)

The method of claim 28, wherein the kinase protein capture agent is a non-selective kinase capture agent.

### Claim 30 (depends on 28)

The method of claim 28, wherein the kinase capture agent is a kinase inhibitor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the kinase inhibitor is staurosporine or a staurosporine analog.

### Claim 32 (depends on 31)

The method of claim 31, wherein the staurosporine analog is selected from the group consisting of 7-hydroxystaurosporine, N-benzoylstaurosporine, 3-hydroxy-4′-N-methylstaurosporine, 3-hydroxy-4′-N-demethylstaurosporine, 3′-demethoxy-3′-hydroxy-4′-N-demethylstaurosporine, staurosporine aglycone and 4′-N-benzoyl staurosporine.

### Claim 33 (depends on 30)

The method of claim 30, wherein the kinase inhibitor is selected from the group consisting of KT 5720, K252, H-9, rottlerin, quercetin, hymenialdisine, SB 203580, myricetin, SU11248, roscovitine, EKB569 and SB202190.

### Claim 34 (depends on 22)

The method of claim 22, wherein the first protein capture agent is labeled with a first member of an affinity pair.

### Claim 35 (depends on 34)

The method of claim 34, wherein the first member of an affinity pair is biotin.

### Claim 36 (depends on 22)

The method of claim 22, wherein the first protein capture agent is a phosphatase capture agent.

### Claim 37 (depends on 36)

The method of claim 36, wherein the phosphatase capture agent is a phosphatase inhibitor.

### Claim 38 (depends on 37)

The method of claim 37, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, tautomycin, microcystin, a microcystin derivative, calyculin A, calyculin B, calyculin C, calyculin D, calyculin E, calyculin F, calyculin G, calyculin H, cantharidin, thyrsferyl 23-acetate, isopalinurin, dragacidin, a dragacidin derivative, fostriecin, 1-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid and bis-(maltoato)-oxovanadium(IV).

### Claim 39 (depends on 22)

The method of claim 22, wherein the protease is trypsin.

### Claim 40 (depends on 22)

The method of claim 22, wherein mass spectroscopy is tandem mass spectroscopy.

### Claim 41 (depends on 40)

The method of claim 40, further comprising:
a) providing to the protein fragments a calibrator peptide having a scissile bond and having the same amino acid composition and same mass as each isobaric mass tag in the set, wherein the calibrator peptide has a scissile bond in a different location from every isobaric mass tag in the set;
b) detecting the calibrator peptide by mass spectrometry; and
c) quantitatively correlating the mass spectrometry signals from the mass tag with the mass spectrometry signals from the calibrator peptide.

### Claim 42

A method for isolating a plurality of proteins from a sample comprising:
a) providing a first kinase capture agent and a second protein capture agent;
b) contacting the sample with the first kinase capture agent and the second protein capture agent;
c) separating the proteins bound to the first kinase capture agent and the second protein capture agent from the sample.

### Claim 43 (depends on 42)

The method of claim 42, wherein the first kinase capture agent is a non-selective kinase capture agent.

### Claim 44 (depends on 42)

The method of claim 42, wherein the first kinase capture agent is a kinase inhibitor.

### Claim 45 (depends on 43)

The method of claim 43, wherein the kinase inhibitor is staurosporine or a staurosporine analog.

### Claim 46 (depends on 45)

The method of claim 45, wherein the staurosporine analog is selected from the group consisting of 7-hydroxystaurosporine, N-benzoylstaurosporine, 3-hydroxy-4′-N-methylstaurosporine, 3-hydroxy-4′-N-demethylstaurosporine, 3′-demethoxy-3′-hydroxy-4′-N-demethylstaurosporine, staurosporine aglycone and 4′-N-benzoyl staurosporine.

### Claim 47 (depends on 42)

The method of claim 42, wherein the first kinase capture agent is labeled with a first member of an affinity pair.

### Claim 48 (depends on 47)

The method of claim 47, wherein the first member of an affinity pair is biotin.

### Claim 49 (depends on 42)

The method of claim 42, wherein the second protein capture agent is a second kinase capture agent different from the first kinase capture agent.

### Claim 50 (depends on 49)

The method of claim 49, wherein the second kinase capture agent is a kinase inhibitor.

### Claim 51 (depends on 50)

The method of claim 50, wherein the second kinase inhibitor is selected from the group consisting of KT 5720, K252, H-9, rottlerin, quercetin, hymenialdisine, SB 203580, myricetin, SU11248, roscovitine, EKB569 and SB202190.

### Claim 52 (depends on 49)

The method of claim 49, wherein the second kinase capture agent is labeled with a first member of an affinity pair.

### Claim 53 (depends on 52)

The method of claim 52, wherein the first member of an affinity pair is biotin.

### Claim 54 (depends on 42)

The method of claim 42, wherein the second protein capture agent is a phosphatase capture agent.

### Claim 55 (depends on 54)

The method of claim 54, wherein the phosphatase capture agent is a phosphatase inhibitor.

### Claim 56 (depends on 55)

The method of claim 55, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, tautomycin, microcystin, a microcystin derivative, calyculin A, calyculin B, calyculin C, calyculin D, calyculin E, calyculin F, calyculin G, calyculin H, cantharidin, thyrsferyl 23-acetate, isopalinurin, dragacidin, a dragacidin derivative, fostriecin, 1-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid and bis-(maltoato)-oxovanadium(IV).

### Claim 57 (depends on 54)

The method of claim 54, wherein the phosphatase capture agent is labeled with a first member of an affinity pair.

### Claim 58 (depends on 57)

The method of claim 57, wherein the first member of an affinity pair is biotin.

### Claim 59

A kit comprising:
a) a capture agent labeled with a first member of an affinity pair;
b) a plate having one or more wells, wherein each well is coated with a second member of the affinity pair; and
c) a set of instructions for use.

### Claim 60 (depends on 59)

The kit of claim 59, wherein the plate has 2, 4, 8, 16, 64, 96, 128, 256, 384 or 512 wells.

### Claim 61 (depends on 60)

The kit of claim 60, further comprising a set of calibrator peptides.

### Claim 62 (depends on 60)

The kit of claim 60, further comprising a set of isobaric mass tags.

### Claim 63 (depends on 60)

The kit of claim 60, wherein the first member of the affinity pair is biotin.

### Claim 64 (depends on 63)

The kit of claim 63, wherein the second member of the affinity pair streptavidin.

### Claim 65 (depends on 60)

The kit of claim 60, wherein the capture agent is a kinase capture agent.

### Claim 66 (depends on 60)

The kit of claim 60, wherein the kinase capture agent is a non-selective kinase capture agent.

### Claim 67 (depends on 65)

The kit of claim 65, wherein the kinase capture agent is a kinase inhibitor.

### Claim 68 (depends on 67)

The kit of claim 67, wherein the kinase inhibitor is staurosporine or a staurosporine analog.

### Claim 69 (depends on 68)

The kit of claim 68, wherein the staurosporine analog is selected from the group consisting of 7-hydroxystaurosporine, N-benzoylstaurosporine, 3-hydroxy-4′-N-methylstaurosporine, 3-hydroxy-4′-N-demethylstaurosporine, 3′-demethoxy-3′-hydroxy-4′-N-demethylstaurosporine, staurosporine aglycone and 4′-N-benzoyl staurosporine.

### Claim 70 (depends on 67)

The kit of claim 67, wherein the kinase inhibitor is selected from the group consisting of KT 5720, K252, H-9, rottlerin, quercetin, hymenialdisine, SB 203580, myricetin, SU11248, roscovitine, EKB569 and SB202190.

### Claim 71 (depends on 60)

The kit of claim 60, wherein the capture agent is a phosphatase capture agent.

### Claim 72 (depends on 71)

The kit of claim 71, wherein the phosphatase capture agent is a phosphatase inhibitor.

### Claim 73 (depends on 72)

The kit of claim 72, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, tautomycin, microcystin, a microcystin derivative, calyculin A, calyculin B, calyculin C, calyculin D, calyculin E, calyculin F, calyculin G, calyculin H, cantharidin, thyrsferyl 23-acetate, isopalinurin, dragacidin, a dragacidin derivative, fostriecin, 1-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid and bis-(maltoato)-oxovanadium(IV).
